Clinical Research Directory

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Sponsor: Canadian Cancer Trials Group

Summary

This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.

Official title: A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma

Key Details

Conditions

Interventions